在线国产一区二区_成人黄色片在线观看_国产成人免费_日韩精品免费在线视频_亚洲精品美女久久_欧美一级免费在线观看

Global EditionASIA 中文雙語(yǔ)Fran?ais
China
Home / China / Health

New vaccine protects the previously infected

By WANG XIAOYU | China Daily | Updated: 2021-09-24 09:59
Share
Share - WeChat
Taxi driver Zheng Ruiwen (front) puts on a protective gown before setting off to transport COVID-19 nucleic acid samples in Putian, Fujian province, on Sept 23, 2021. [Photo by ZHANG BIN/CHINA NEWS SERVICE]

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

The vaccine candidate is 92 percent effective against the Gamma variant first identified in Brazil, and 59 percent against the Mu variant first detected in Colombia, according to joint statement issued by the company and the Coalition for Epidemic Preparedness Innovations, a nonprofit organization that funded the clinical trial.

The vaccine's overall efficacy rate against all strains in the study was 67 percent. It was also 100 percent effective in preventing severe cases and hospitalizations, and nearly 84 percent effective in preventing moderate to severe cases, the statement said.

The vaccine is the "first COVID-19 vaccine to demonstrate significantly reduced risk of COVID-19 disease in previously infected individuals, a growing and increasingly important population as SARS-CoV-2(the novel coronavirus that causes the disease) continues to spread globally", it said.

The protein-based vaccine uses protein fragments of the virus to trigger immune responses, and requires the use of an adjuvant to achieve desired protection.

Clover Biopharmaceuticals, which is based in Chengdu, Sichuan province, said its adjuvant is supplied by the US company Dynavax.

More than 30,000 adults-some of them elderly-in the Philippines, Brazil, Colombia, South Africa and Belgium were enrolled in mid- and late-stage clinical trials. They were either given two doses administered 21 days apart or a placebo.

Like the inactivated vaccines widely deployed in China, the experimental vaccine can be stored at regular refrigerated temperatures of 2 to 8 C, making its transportation and distribution easier.

The company said it plans to submit applications for conditional market approval to global regulatory authorities in the fourth quarter of the year and is aiming for a potential market launch by the end of the year.

Clover Biopharmaceuticals is also a supplier to COVAX, an international initiative that distributes vaccines to low- and middle-income countries.

The company signed an advance purchase agreement with Gavi, one of the co-leaders of COVAX, in late June to provide 414 million doses of its vaccine to the initiative by next year.

However, the product has to first gain emergency use authorization from the World Health Organization, which is anticipated in the fourth quarter of this year, according to Gavi.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 欧美性网| 成人一区二区三区视频 | 午夜精品久久久久久久99黑人 | 国产精品久久精品 | 一片毛片| 四虎成人永久 | 久久免费国产 | 日韩亚洲视频 | 久久久一区二区三区捆绑sm调教 | 影音先锋中文字幕在线 | 女人夜夜春高潮爽a∨片传媒 | 久久精品视频网站 | 欧美三级免费 | 91视频污黄 | 免费国产黄网站在线观看视频 | 日本久久网 | 九九精品在线 | 中文字幕精品一区二区三区精品 | 黄色网址免费在线 | 日韩在线视频一区 | 亚洲欧洲综合av | 久久精品1区2区 | 亚洲午码 | 午夜a级理论片915影院 | 羞羞视频网站在线看 | 精品亚洲一区二区三区 | 天堂资源最新在线 | 国产成人一区二区 | 久久夜夜 | 国产一区不卡 | 亚洲一级性生活片 | 黄色影视在线 | 免费观看一级特黄欧美大片 | 国产精品久久久久久一区二区三区 | 国产精品二区三区 | 日韩激情一区二区 | 91亚洲在线| 谁有毛片网址 | 日韩av在线免费 | 在线成人av | 国产一区二区三区四区在线观看 |